



Review

Epigenetics of cell fate reprogramming and its implications for neurological disorders modelling



Maciej Grzybek^{a,b}, Aleksandra Golonko^c, Marta Walczak^d, Pawel Lisowski^{b,e,*}

^a Faculty of Veterinary Medicine, University of Life Sciences in Lublin, Akademicka 12, 20-950 Lublin, Poland

^b Department of Molecular Biology, Institute of Genetics and Animal Breeding, Polish Academy of Sciences, Jastrzębiec, Postępu 36A, 05-552 Magdalenka, Poland

^c Department of Biotechnology, Faculty of Civil and Environmental Engineering, Białystok University of Technology, Wiejska 45E, 15-351 Białystok, Poland

^d Department of Animal Behavior, Institute of Genetics and Animal Breeding, Polish Academy of Sciences, Jastrzębiec, Postępu 36A, 05-552 Magdalenka, Poland

^e iPS Cell-Based Disease Modelling Group, Max Delbrück Center for Molecular Medicine (MDC) in the Helmholtz Association, Robert-Rössle-Str. 10, 13092 Berlin, Germany

ARTICLE INFO

Article history:

Received 4 May 2016

Revised 3 November 2016

Accepted 21 November 2016

Available online 23 November 2016

Keywords:

Epigenetics

Epigenomics

Stem cell reprogramming

Neuronal differentiation

Neurological disorders

Genome editing

Stem cell technologies

iPS cell based disease modelling

ABSTRACT

The reprogramming of human induced pluripotent stem cells (hiPSCs) proceeds in a stepwise manner with reprogramming factors binding and epigenetic composition changes during transition to maintain the epigenetic landscape, important for pluripotency. There arises a question as to whether the aberrant epigenetic state after reprogramming leads to epigenetic defects in induced stem cells causing unpredictable long term effects in differentiated cells. In this review, we present a comprehensive view of epigenetic alterations accompanying reprogramming, cell maintenance and differentiation as factors that influence applications of hiPSCs in stem cell based technologies. We conclude that sample heterogeneity masks DNA methylation signatures in subpopulations of cells and thus believe that beside a genetic evaluation, extensive epigenomic screening should become a standard procedure to ensure hiPSCs state before they are used for genome editing and differentiation into neurons of interest. In particular, we suggest that exploitation of the single-cell composition of the epigenome will provide important insights into heterogeneity within hiPSCs subpopulations to fast forward development of reliable hiPSC-based analytical platforms in neurological disorders modelling and before completed hiPSC technology will be implemented in clinical approaches.

© 2016 Elsevier Inc. All rights reserved.

Contents

1. Introduction	85
2. Epigenetics of pluripotency	86
2.1. Non-CpG methylation in pluripotency	87
2.2. Non-coding RNAs in pluripotency	87
2.3. Oxidation of 5mC (5hmC) and pluripotency	87
2.4. Promoters and enhancers	88
2.5. Metabolism-epigenetic crosstalk in PSCs	88
3. Epigenetic alterations in pluripotent cells	89
3.1. Unpredictable epigenomic changes associated with reprogramming	89
3.2. Epigenetic instability during in vitro culture – lessons from ES cells	90
3.3. Alterations in imprinting and X-chromosome inactivation patterns in hiPSCs	90
3.4. Alterations in DNA methylation	91
3.5. Cancer-associated epigenetic alterations in cultured pluripotent cells	91
3.6. Alterations in histone modification patterns	91
3.7. Epigenetic heterogeneity among PSCs	92

* Corresponding author at: Department of Molecular Biology, Institute of Genetics and Animal Breeding, Polish Academy of Sciences, Jastrzębiec, Postępu 36A, 05-552 Magdalenka, Poland.

E-mail addresses: grzybek.genetics@gmail.com (M. Grzybek), olau.95@gmail.com (A. Golonko), martawalczak@yahoo.com (M. Walczak), pawel.lisowski@mdc-berlin.de (P. Lisowski).

Available online on ScienceDirect (www.sciencedirect.com).

4.	Epigenetics of reprogramming	92
4.1.	Epigenetic mechanisms during cell reprogramming to iPSC.	92
4.2.	DNA methylation during reprogramming to iPSC	93
5.	Epigenetic induction of pluripotency to maintain epigenetic state	95
5.1.	Epigenetics of naive pluripotency	95
5.2.	Small molecules modulating naive pluripotency.	95
5.3.	miRNA-induced naive pluripotency	96
5.4.	mRNA methylation facilitates resolution of naive pluripotency	97
6.	Epigenetic regulation of differentiation	97
6.1.	Epigenetic mechanisms during neural cell differentiation	97
7.	Epigenetic implications for neurological disorders modelling	98
7.1.	Epigenetics and its role in neurodegeneration.	98
7.2.	Implication of 5-hydroxymethylcytosine (5hmC) for neurological disorders	103
7.3.	Epigenetic implications for late onset disease modelling – hiPSCs and ageing.	104
8.	Single-cell sequencing as a method of addressing an expanding set of limitations in iPSC cell based technologies	105
8.1.	Cellular reprogramming creates epigenetic heterogeneity revealed by single-cell profiling.	105
8.2.	Exit from pluripotency creates epigenetic heterogeneity revealed by single-cell profiling.	105
8.3.	Microenvironmental impact on the regulation of pluripotency in neural stem cells revealed by single-cell profiling	106
8.4.	Monitoring of signalling cross-talk between regulatory levels for prediction of stem cell heterogeneity using single-cell sequencing data.	106
9.	The need for reference maps of pluripotent cell lines	108
9.1.	Progression towards bone fide human neurological disease modelling.	108
10.	Conclusions and future perspectives	109
	Conflict of interest	109
	Acknowledgements	109
	References	109

1. Introduction

Pluripotent cells, which are capable of producing all somatic cell types, provide a valuable resource for developmental studies and regenerative therapies (Ross and Akimov, 2014; Unternaehrer and Daley, 2011). Human embryonic stem cell (hESC) lines can be derived from the inner cell mass of early blastocyst embryos and maintained in vitro (Chan et al., 2013). The unique identity of ESCs is governed by a network of transcriptional factors along with epigenetic factors. The epigenetic status of ESCs features an open chromatin structure with characteristic histone and DNA modification profile (Liang and Zhang, 2013).

Alternatively, human induced pluripotent stem cells (hiPSCs) can be reprogrammed from somatic cells (Lund et al., 2012). Reprogramming of somatic cells to pluripotency can currently be achieved by somatic cell nuclear transfer (SCNT) (Whitworth and Prather, 2010), fusion of somatic and pluripotent cells (Niemann et al., 2008), ectopic expression of defined sets of pluripotency transcription factors (TFs) OCT4, SOX2, KLF4, and MYC (OSKMs) in somatic cells to generate induced pluripotent stem cells (iPSCs) (Takahashi et al., 2007). Somatic cells could also be directly reprogrammed to induced cells e.g. induced neurons (iN) though the use of empirically determined cocktails of neurogenic factors (Han et al., 2012). The first clinical trials using embryonic-stem-cell-derived products have begun (Schwartz et al., 2012).

hiPSCs derived from patients with genetic diseases can be used as cellular models of a disease, thus enabling mechanistic studies and high throughput drug screenings (Lund et al., 2012). Recent findings underline the significant role that hiPSC models can play in epigenetic research to generate patient-specific disease-relevant cells to elucidate disease mechanisms (Qiang et al., 2013). Reprogramming of human fibroblasts into hiPSCs has become a widely applied technique used to create models of neurodegenerative and neurological disorders (Imaizumi and Okano, 2014). Well-described protocols are available to generate patient-derived disease-relevant cell types upon hiPSCs reprogramming. Until now hiPSC models have been applied in order to study a broad spectrum of neurodegenerative disorders (Durnaoglu et al., 2011) including Huntington's disease (Zhang et al., 2010), Parkinson's disease (Byers et al., 2012; Soldner et al., 2009), Amyotrophic Lateral Sclerosis (Bohl et al., 2016), Frontotemporal Dementia (Almeida et al., 2013), Alzheimer's disease (Hossini et al., 2015; D.

Zhang et al., 2014), Spinomuscular Atrophy (Ebert et al., 2009; Ebert and Svendsen, 2010) and other polyglutamine diseases (Ross and Akimov, 2014). However, the genetic and potentially epigenetic heterogeneity of stem cell lines contributes to the functional variability of differentiated somatic cells, confounding evaluation of disease modelling experiments (Ichida and Kiskinis, 2015; Sandoe and Egan, 2013).

In pluripotent cells the accumulation of epigenomic alterations is a concern and it is thus an area of active research. Such variability can be introduced at multiple levels of reprogramming including OSKMs action, in vitro culture, variation in cell culture reagents, and neural generation (Fig. 1).

Reprogramming is a multi-step process characterised by two waves of transcriptome and proteome resetting (Sancho-Martinez and Belmonte, 2013). Early in the reprogramming process, OSKMs induce stochastic gene expression changes in a subset of pluripotency genes which are critical for instigation of the second phase (Buganim et al., 2013). The epigenetic signature of the somatic cell must be erased during the conversion in order to adopt a stem cell-like epigenome. These changes include chromatin reorganisation, DNA demethylation of the promoter regions of pluripotency genes like *Nanog*, *Sox2* and *Oct4*, reactivation of the somatically silenced X chromosome, and genome-wide resetting of histone posttranslational modifications. Confirmation of genetic cell identity is necessary, yet does not provide a full picture of crucial information. Knowledge of the cell state, pluripotency, and other cellular characteristics is not sufficiently advanced at this stage to permit a comprehensive cellular profile based solely on genetic analysis, even with genome sequencing. Table 1 shows the major issues and potential solutions for hiPSC quality control as well contemporary methods of quality testing.

Epigenetic changes, metabolic reprogramming, mitochondrial alterations and remnants of reprogramming components may cause changes in cellular behavior, function and properties (Yaffe et al., 2016). An understanding of the intrinsic properties of stem cells i.e. their pluripotency, self-renewal, and regulatory mechanisms is crucial for the modelling of human diseases. However, a full understanding of how pluripotency and somatic cell reprogramming are controlled is still lacking, meaning that alongside biological cell and molecular mechanisms, the epigenetics underlying these properties becomes of crucial interest (Yaffe et al., 2016).

Download English Version:

<https://daneshyari.com/en/article/5630675>

Download Persian Version:

<https://daneshyari.com/article/5630675>

[Daneshyari.com](https://daneshyari.com)